Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

The study includes two cohorts: (1) a serological screening cohort; (2) a serological and EBV DNA screening cohort. All participants will be tested for EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab), with additional plasma EBV DNA testing in the latter cohort. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.

Inclusion Criteria: * Subject residents in Zhongshan City or Wuzhou City * Subject has no medical record of nasopharyngeal carcinoma * ECOG 0-2 * Subject is able to comprehend, sign, and date the written informed consent document to participate in the study. * Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study. Exclusion Criteria: * Subject has heavy cardiovascular, liver or kidney disease. * Subject has contraindications to nasopharyngeal fiberoptic endoscopy.